↑ 疾患リストへ ← 戻る

 333. ハッチンソン・ギルフォード症候群 [臨床試験数:5,薬物数:5(DrugBank:3),標的遺伝子数:4,標的パスウェイ数:2] 

Searched query = "Hutchinson-Gilford syndrome", "Hutchinson-Gilford progeria syndrome", "HGPS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03895528August 201929 July 2019Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid LaminopathyA Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid LaminopathyProgeria;HGPSDrug: LonafarnibEiger BioPharmaceuticalsNot recruiting12 MonthsN/AAllPhase 3
2NCT03871972March 5, 20196 May 2019Umbilical Cord Blood Transfusion in Progeria SyndromeSafety and Efficacy of Umbilical Cord Blood Transfusion in Patients With Hutchinson-Gilford Progeria SyndromeHutchinson-Gilford Progeria SyndromeDrug: Umbilical Cord Blood UnitBundang CHA HospitalRecruitingN/AN/AAll2Phase 1/Phase 2Korea, Republic of
3NCT00916747August 200924 June 2019Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaAn Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid LaminopathiesProgeriaDrug: Lonafarnib, Zoledronic Acid, and PravastatinBoston Children’s HospitalSchering-Plough;Merck Sharp & Dohme Corp.RecruitingN/AN/AAll85Phase 2United States
4NCT00879034March 200924 June 2019A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaA Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: Lonafarnib;Drug: Zoledronic Acid;Drug: PravastatinBoston Children’s HospitalDana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-PloughNot recruitingN/AN/AAll5Phase 2United States
5NCT00425607May 200711 June 2018Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for ProgeriaAn Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: LonafarnibMonica E. KleinmanSchering-PloughNot recruiting1 YearN/AAll29Phase 2United States

先頭へ